US 12,109,202 B2 · Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders

Abstract

The present invention includes a method for improving cognitive function in a human suffering from a neurodegenerative cognitive disorder. The method comprises administering to a patient a total daily dose of a cholinesterase inhibitor and a quaternary ammonium antimuscarinic compound. The total daily dose is divided into one or more doses administered before food intake. The quaternary ammonium antimuscarinic compound is administered in a first drug delivery element configured for rapid absorption into a body of the patient, and the cholinesterase inhibitor is administered in a second drug delivery element configured for a slower or delayed absorption into the body of the patient.

Claims5

Dependent claims

A drug delivery element comprising:

a first portion configured to release a therapeutic amount of 2-8 mg of a quaternary ammonium antimuscarinic compound into the human body, the first portion having a first dissolve rate;
and
a second portion configured to release a therapeutic amount of 3-48 mg of a cholinesterase inhibitor into a human body, the second portion having a second dissolve rate,
wherein the first dissolve rate is faster than the second dissolve rate.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

17/163,010Filed 29 Jan 2021

Published

US 2022/0241254 A14 Aug 2022

Granted

8 Oct 2024

Term ends

Not estimatedThe source records don’t support an estimate.

Classification15 codes

A61K 31/27
Esters, e.g. nitroglycerine, selenocyanates: of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
A61K 31/438
Having six-membered rings with one nitrogen as the only ring hetero atom: the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 9/0053
Galenical forms characterised by the site of application: mouth and digestive tract, i.e. intraoral and peroral administration
A61K 9/4825
Wall or shell material: proteins, e.g. gelatin

Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders

Life of this patent

Fixed dose combination of cholinesterase inhibitor and a quaternary ammonium antimuscarinic agent to treat neurodegenerative cognitive disorders

Life of this patent

Abstract

Claims5